https://biotechmorning.com/news/kerendia-type-1-diabetes-ckd-approval Biotech Morning en 2026-09-17T14:17:19.125Z 30 Years Without a New Drug. Type 1 Diabetes Patients Just Got One. https://biotechmorning.com/news/pd1-agonist-rheumatoid-arthritis-jak-like-efficacy Biotech Morning en 2026-09-17T14:16:38.728Z A Cancer Drug's Evil Twin Might Be the Best Thing to Happen to Arthritis https://biotechmorning.com/news/novartis-sironax-brain-delivery-platform-deal Biotech Morning en 2026-09-17T14:15:55.266Z Novartis Just Paid $125M for a Key to the Brain's Front Door https://biotechmorning.com/news/pfizer-10-billion-metsera-obesity-acquisition Biotech Morning en 2026-09-17T14:15:02.691Z Pfizer Just Spent $10 Billion to Crash the Obesity Party https://biotechmorning.com/news/lilly-twist-bioscience-tunelab-ai-antibody-discovery Biotech Morning en 2026-09-17T14:14:16.972Z Lilly's Secret Weapon for Finding Better Antibodies Isn't a Lab https://biotechmorning.com/news/acelot-oral-tdp43-als-drug-first-dosing Biotech Morning en 2026-09-17T14:13:33.890Z The Pill Chasing ALS's Most Elusive Target https://biotechmorning.com/news/skyhawk-huntingtons-rna-splicing-therapy-15-month-data Biotech Morning en 2026-09-17T14:12:43.138Z The Huntington's Drug That's Doing What Others Couldn't https://biotechmorning.com/news/oral-pill-thyroid-eye-disease-sling-therapeutics Biotech Morning en 2026-09-17T14:12:00.482Z The Pill That Wants to Kill a $2 Billion Needle https://biotechmorning.com/news/roche-dualitas-bispecific-antibody-screening-deal Biotech Morning en 2026-09-17T14:11:16.044Z Roche Just Paid $36.5M for a Machine That Tests 300,000 Antibody Combos https://biotechmorning.com/news/novo-nordisk-anthropic-claude-ai-drug-development Biotech Morning en 2026-09-17T14:10:22.354Z Novo Nordisk Just Hired the Brainiest AI in the Room https://biotechmorning.com/news/ge-healthcare-sofie-biosciences-acquisition Biotech Morning en 2026-09-16T14:17:28.103Z GE HealthCare Wants to Buy the Bullets for Its Own Guns https://biotechmorning.com/news/fda-operation-trialblazer-accelerate-phase-1-trials Biotech Morning en 2026-09-16T14:16:42.969Z The FDA Wants to Shave a Year Off Your Drug's Timeline https://biotechmorning.com/news/astrazeneca-15-billion-ivonescimab-summit-deal Biotech Morning en 2026-09-16T14:15:56.704Z AstraZeneca's $15 Billion Bet on a Drug You've Never Heard Of https://biotechmorning.com/news/roche-hanmi-obesity-muscle-preservation-deal Biotech Morning en 2026-09-16T14:15:12.036Z Roche's $2.3 Billion Bet on a Muscle That Won't Quit https://biotechmorning.com/news/sionna-therapeutics-cystic-fibrosis-layoffs Biotech Morning en 2026-09-16T14:14:26.213Z The $330M Bet on Fixing a Broken Protein That Just Blew Up https://biotechmorning.com/news/ai-drug-rentosertib-phase-3-pulmonary-fibrosis Biotech Morning en 2026-09-16T14:13:43.367Z An AI Built This Drug From Scratch. Now It Faces Its Biggest Test. https://biotechmorning.com/news/lilly-2-9-billion-merida-biosciences-acquisition Biotech Morning en 2026-09-16T14:12:55.471Z Lilly's $2.9 Billion Bet on a Company You've Never Heard Of https://biotechmorning.com/news/lutathera-first-generic-radioligand-copycat Biotech Morning en 2026-09-16T14:12:14.110Z Lutathera Just Got Its First Copycat. Radioligand Therapy Will Never Be the Same. https://biotechmorning.com/news/merck-kgaa-bio-techne-11-billion-acquisition-2 Biotech Morning en 2026-09-16T14:11:29.063Z Merck KGaA Just Made Its Biggest Bet in a Decade. Here's What It's Buying.